• Delic Holdings Co-founder and CEO, Matt Stang, will take part in three upcoming conferences – the Scottdale Capital Event, the Planet MicroCap Showcase, and the H.C. Wainwright Annual Global Life Sciences Conference
• In presentations and one-on-one meetings, Stang will discuss Delic’s new revenue lines and strategic outlook for the remainder of the year
• During a recent interview on The Jesse Tee Show, Stang noted the company intends to scale its ketamine clinics as well as build infrastructure to accommodate expanded psychedelic healing 
• The company hopes to utilize its expanded infrastructure to help destigmatize mental health conditions 

Delic Holdings (CSE: DELC) (OTCQB: DELCF), a company on a mission to provide research, high-quality products, education, and effective treatment options and reframe the psychedelic conversation, recently revealed its Co-founder and CEO, Matt Stang, will take part in a series of upcoming investor conferences scheduled for this spring (https://ibn.fm/PgYbu). Staggered between April and May, the events will see Stang share the company’s new revenue lines and strategic outlook for the rest of the year.

At the 10th Annual Scottsdale Capital Event, scheduled for April 22-24, Stang will participate in one-on-one meetings that will look into Delic’s strategic outlook for the rest of the year. Hosted by Capital Event Management at the Fairmont Scottsdale Princess Resort in Scottdale, Arizona, the three-day event is designed to provide institutional investors, high net worth individuals, portfolio managers, and investment advisors to listen to growing companies’ stories and subsequently invest (https://ibn.fm/H4hF1).

On May 4, Stang will present at the Planet MicroCap Showcase, a leading in-person event in MicroCap Finance. Stang’s presentation will focus on Delic’s business outlook and growth opportunities for the second half of the year. Like the Scottsdale Capital Event, the three-day Planet MicroCap Showcase, set to be held in Las Vegas, is expected to bring together the premier dealmakers and the most promising organizations.

Closing out the series of events is the H.C. Wainwright Annual Global Life Sciences Conference, a hybrid event to be held in Miami, Florida, from May 23 through May 26. During a scheduled presentation, whose recording will be availed from June 10, Stang will detail Delic’s expansion strategy and industry outlook. He will also take part in one-on-one meetings.

The common theme of Stang’s presentations and one-on-one meetings is Delic’s growth throughout the remainder of the year. And during a recent interview on The Jesse Tee Show, Stang offered a glimpse into this outlook, possibly pointing to what attendees are likely to hear. When asked about the direction he anticipates Delic to take, for example, Stang discussed the fact that the company seeks to scale (https://ibn.fm/ak4U8).

“Being the largest clinic chain in America today, [we look to grow] that exponentially over the next couple of years. We think that the real opportunity is to be in the top 50 or top 100 markets with the clinics, where [people] can get safe, effective, and beneficial care. We want people to feel like there is a solution in their backyard,” said Stang. “The opportunity is to build this thing to a scale where you will see one of our clinics somewhere within 30 minutes of you.”

Delic owns and operates an umbrella of brands, including Ketamine Wellness Centers (“KWC”), which constitute the United States’ largest retail and physical footprint of ketamine clinics. While the clinics currently focus on treating mental health conditions using ketamine infusions, Stang noted the company’s outlook for the future also considers other new treatment options, including psilocybin and MDMA (ecstasy), two psychoactive drugs likely to be approved by the Food and Drug Administration (“FDA”) in the coming years, according to a report by the New York Times (https://ibn.fm/nXclX).

Additionally, the company intends to build the infrastructure for psychedelic healing, enabling it to effectively adopt better treatments as new molecules are developed and approved. “Each person is so individual and different, and I think having a larger number of [psychedelic treatment options] to try – and they are all so powerful and beneficial in their own ways – is going to change how people interact with and talk about mental health. We can destigmatize mental health conditions,” Stang continued.

As part of his presentations during the upcoming investor conferences, Stang is likely to reiterate these sentiments, constraining his outlook to 2022. This is expected to offer insights that could potentially influence investors’ investment in the fast-growing company.

For more information, visit the company’s website at www.DelicCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.